The global botulinum toxin market (ボツリヌス毒素市場) is expected to witness substantial growth, with an estimated valuation of US$ 6.83 billion in 2024, projected to reach US$ 13.14 billion by 2034. This represents a robust compound annual growth rate (CAGR) of 6.8% during the forecast period. According to a study by Fact.MR, a market research and competitive intelligence provider, North America is expected to lead in terms of botulinum toxin sales from 2024 to 2034. The increasing global geriatric population and the growing emphasis on aesthetic appearance are key drivers for the growth of the botulinum toxin market over the next decade. The rising influence of social media has heightened the importance of physical appearance, driving demand for cosmetic procedures. This, combined with the increasing availability of such procedures, is expected to create favorable conditions for botulinum toxin companies. Overall, the outlook for the global botulinum toxin market is promising, with significant growth potential driven by demographic trends and evolving consumer preferences.
Get Free Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9303
In contrast, lack of favorable reimbursements for treatments utilizing botulinum toxin and the growing availability of counterfeit products that have significant side effects are predicted to hamper botulinum toxin sales in the future. Botulinum toxin manufacturing companies are focusing on collaborating with health insurance companies to improve the reimbursement scenario all over the world.
Key Takeaways from Market Study
- The global botulinum toxin market (보툴리눔 독소 시장) is estimated at US$ 6.83 billion in 2024.
- Demand for botulinum toxin is set to rise at a CAGR of 6.8% from 2024 to 2034.
- The market is forecasted to attain a valuation of US$ 13.14 billion by 2034-end.
- Increasing geriatric population, rising availability of minimally invasive cosmetic surgeries, increasing demand for anti-aging products, and growing willingness of consumers to spend on aesthetic wellness are key market drivers.
- Sales of botulinum toxin in the United States are set to increase at 7.1% CAGR over the next 10 years.
- Botulinum toxin sales in Latin America are predicted to reach US$ 530 million by 2034.
- Type A botulinum toxin is forecasted to account for 99.3% of global market revenue in 2024.
Winning Strategy
Botulinum toxin manufacturers are projected to focus on getting their new products approved by regulatory authorities to fast-track the commercialization process and stand out from the competition. Botulinum toxin companies are also forecasted to make efforts to improve the reimbursement landscape for treatments involving the use of botulinum toxin.
Key Companies Profiled in This Report
- Merz Pharma GmbH & Co. KGaA
- Hugel
- Allergan PLC
- Hugh Source (International) Ltd.
- Ipsen
- Medy-Tox
- U.S. WorldMeds
- Daewoong Pharmaceuticals
Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=9303
Competitive Landscape:
Major botulinum toxin brands are actively seeking approvals to expand their market presence globally. These companies are also investing significantly in research and development to introduce innovative botulinum toxin medications and accelerate the commercialization process. For example, in September 2023, Hugel Inc., a prominent South Korean biopharmaceutical company specializing in botulinum toxin (Botulinumtoxin-Markt), announced the resubmission of its product approval applications for Letybo to the United States Food & Drug Administration (FDA). Letybo is Hugel's botulinum toxin preparation that was previously rejected by the FDA earlier in the year.
About Fact.MR :
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.
Contact:
US Sales Office
11140 Rockville Pike
Suite 400 Rockville, MD 20852
United States Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Sales Team: sales@factmr.com